{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:25:37Z","timestamp":1779384337459,"version":"3.53.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104267","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T16:44:18Z","timestamp":1733935458000},"page":"104267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primary systemic amyloidosis: A brief overview"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8042-5006","authenticated-orcid":false,"given":"Michael Sang","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2024.104267_bib0001","first-page":"135","article-title":"Ueber eine im Gehirn und R\u00fcckenmark des Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose","volume":"6","author":"Virchow","year":"1854","journal-title":"Archiv f\u00fcr pathologische Anatomie und Physiologie und f\u00fcr klinische Medicin"},{"key":"10.1016\/j.lpm.2024.104267_bib0002","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104267_bib0003","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728214.2020.1803829","article-title":"Emerging drugs for the treatment of light chain amyloidosis","volume":"25","author":"Chakraborty","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.lpm.2024.104267_bib0004","first-page":"67","article-title":"Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.lpm.2024.104267_bib0005","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104267_bib0006","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0007","series-title":"Janeway's immunobiology","author":"Murphy","year":"2017"},{"key":"10.1016\/j.lpm.2024.104267_bib0008","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264407","article-title":"Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement","volume":"17","author":"Berghaus","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.lpm.2024.104267_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1008449","article-title":"Understanding AL amyloidosis with a little help from in vivo models","volume":"13","author":"Martinez-Rivas","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lpm.2024.104267_bib0011","doi-asserted-by":"crossref","first-page":"27513","DOI":"10.1074\/jbc.M114.585638","article-title":"Formation of amyloid fibers by monomeric light chain variable domains","volume":"289","author":"Brumshtein","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lpm.2024.104267_bib0012","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1021\/acs.biochem.7b00579","article-title":"Incomplete refolding of antibody light chains to non-native, protease-sensitive conformations leads to aggregation: a mechanism of amyloidogenesis in patients?","volume":"56","author":"Morgan","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.lpm.2024.104267_bib0013","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107174","article-title":"Truncation of the constant domain drives amyloid formation by immunoglobulin light chains","volume":"300","author":"Lavatelli","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lpm.2024.104267_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41467-021-21126-2","article-title":"Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis","volume":"12","author":"Radamaker","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2024.104267_bib0016","doi-asserted-by":"crossref","first-page":"16572","DOI":"10.1074\/jbc.RA120.013461","article-title":"Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis","volume":"295","author":"Lavatelli","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lpm.2024.104267_bib0017","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra2304088","article-title":"Systemic light chain amyloidosis","volume":"390","author":"Sanchorawala","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104267_bib0018","doi-asserted-by":"crossref","first-page":"19813","DOI":"10.1074\/jbc.M116.736736","article-title":"Cell damage in light chain amyloidosis: fibril internalization, toxicity and cell-mediated seeding","volume":"291","author":"Marin-Argany","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.lpm.2024.104267_bib0019","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lpm.2024.104267_bib0020","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00395-013-0378-5","article-title":"Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity","volume":"108","author":"Guan","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.lpm.2024.104267_bib0021","doi-asserted-by":"crossref","first-page":"H1158","DOI":"10.1152\/ajpheart.00788.2018","article-title":"Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration","volume":"316","author":"Mishra","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.lpm.2024.104267_bib0022","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0023","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.kint.2023.11.023","article-title":"A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis","volume":"105","author":"Charalampous","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.lpm.2024.104267_bib0024","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","article-title":"Cardiac amyloidosis: a practical approach to diagnosis and management","volume":"124","author":"Kapoor","year":"2011","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.lpm.2024.104267_bib0025","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jcmg.2024.05.004","article-title":"Myocardial characteristics, cardiac structure, and cardiac function in systemic light-chain amyloidosis","volume":"17","author":"Clerc","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2024.104267_bib0026","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/bloodadvances.2020003782","article-title":"Prognostic restaging after treatment initiation in patients with AL amyloidosis","volume":"5","author":"Abdallah","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.lpm.2024.104267_bib0027","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41375-019-0400-5","article-title":"Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis","volume":"33","author":"Hwa","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2024.104267_bib0028","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0029","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120341","article-title":"Prevalence and predictors of neurological manifestations in systemic AL amyloidosis","volume":"440","author":"Thimm","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.lpm.2024.104267_bib0031","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jama.1983.03330340064034","article-title":"Bleeding manifestations in 100 patients with amyloidosis","volume":"249","author":"Yood","year":"1983","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2024.104267_bib0032","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.mayocp.2020.06.061","article-title":"Coagulation abnormalities in light chain amyloidosis","volume":"96","author":"Abdallah","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2024.104267_bib0033","doi-asserted-by":"crossref","first-page":"e1577","DOI":"10.1097\/TXD.0000000000001577","article-title":"Lung transplantation for pulmonary AL amyloidosis","volume":"10","author":"Ehrlich","year":"2024","journal-title":"Transplant Direct"},{"key":"10.1016\/j.lpm.2024.104267_bib0034","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.6004\/jnccn.2022.7077","article-title":"Immunoglobulin light chain amyloidosis: diagnosis and risk assessment","volume":"21","author":"Zanwar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.lpm.2024.104267_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2024.105628","article-title":"Salivary gland amyloidosis: proteomic identification and clinicopathologic characterization of 57 cases","volume":"151","author":"Chiu","year":"2024","journal-title":"Hum Pathol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104267_bib0037","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jchf.2024.07.007","article-title":"Functional status and quality of life in light-chain amyloidosis: advanced imaging, longitudinal changes, and outcomes","volume":"12","author":"Clerc","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.lpm.2024.104267_bib0038","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jaccao.2022.08.007","article-title":"Low QRS voltages in cardiac amyloidosis: clinical correlates and prognostic value","volume":"4","author":"Cipriani","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0039","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2-diagnostic criteria and appropriate utilization","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2024.104267_bib0040","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2215\/CJN.11161111","article-title":"Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases","volume":"7","author":"Leung","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.lpm.2024.104267_bib0041","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2024.104267_bib0042","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0043","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0044","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0045","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1002\/ehf2.13652","article-title":"History of extracardiac\/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis","volume":"8","author":"Kharoubi","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.lpm.2024.104267_bib0046","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0047","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0048","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2024.2629","article-title":"Graded organ response and progression criteria for kidney immunoglobulin light chain amyloidosis","author":"Muchtar","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0050","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2022.2157581","article-title":"Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis","volume":"28","author":"Kastritis","year":"2023","journal-title":"Hematology"},{"key":"10.1016\/j.lpm.2024.104267_bib0051","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0052","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/ejh.13554","article-title":"Characterization and prognostic implication of delayed complete response in AL amyloidosis","volume":"106","author":"Muchtar","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0053","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00432-024-05733-2","article-title":"Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0054","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2024.104267_bib0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2024024623","article-title":"Patients with a cardiac complete response in AL amyloidosis have survival rates similar to those of a matched general population","volume":"144","author":"Muchtar","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0056","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104267_bib0057","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0058","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V52.4.818.818","article-title":"Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo","volume":"52","author":"Kyle","year":"1978","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0059","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/0002-9343(85)90521-2","article-title":"Primary systemic amyloidosis. Comparison of melphalan\/prednisone versus colchicine","volume":"79","author":"Kyle","year":"1985","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2024.104267_bib0060","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V91.10.3662","article-title":"Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients","volume":"91","author":"Comenzo","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0061","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.11325","article-title":"Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone","volume":"92","author":"Kastritis","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2024.104267_bib0062","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0063","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-019-0266-9","article-title":"Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis","volume":"10","author":"Warsame","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104267_bib0064","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41409-024-02301-7","article-title":"High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy","volume":"59","author":"Mellgard","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.lpm.2024.104267_bib0065","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/ajh.26641","article-title":"Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: a 25-year longitudinal study","volume":"97","author":"Gustine","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0066","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2147\/TCRM.S325859","article-title":"Safety and efficacy of subcutaneous daratumumab in systemic AL amyloidosis","volume":"19","author":"Hughes","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.lpm.2024.104267_bib0067","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104267_bib0068","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.18733","article-title":"First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy","volume":"201","author":"Chakraborty","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0069","first-page":"220","article-title":"Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival","volume":"109","author":"Oubari","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.lpm.2024.104267_bib0070","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/s41375-024-02243-5","article-title":"Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures","volume":"38","author":"Zanwar","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2024.104267_bib0071","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104267_bib0072","first-page":"1","article-title":"Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy","author":"Dima","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.lpm.2024.104267_bib0073","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/ejh.13993","article-title":"Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies","volume":"111","author":"Fotiou","year":"2023","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104267_bib0074","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/ajh.27450","article-title":"Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis","volume":"99","author":"Bazarbachi","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0075","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase ii study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0076","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104267_bib0077","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0078","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1158\/1078-0432.CCR-22-0637","article-title":"Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis","volume":"28","author":"Kfir-Erenfeld","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lpm.2024.104267_bib0079","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14293","article-title":"Safety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed\/refractory multiple myeloma and concurrent light chain amyloidosis","author":"Goel","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000508262","article-title":"Solid organ transplantation in amyloidosis","volume":"143","author":"Theodorakakou","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0081","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0082","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104267_bib0083","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104267_bib0084","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000506760","article-title":"supportive care in AL amyloidosis","volume":"143","author":"Cibeira","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0085","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025899","article-title":"Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy","author":"Chakraborty","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lpm.2024.104267_bib0086","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/ajh.27472","article-title":"Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease","volume":"99","author":"Anand","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.lpm.2024.104267_bib0087","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104267_bib0088","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.lpm.2024.104267_bib0089","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamacardio.2024.2555","article-title":"Redefining cardiac involvement and targets of treatment in systemic immunoglobulin AL amyloidosis","volume":"9","author":"Porcari","year":"2024","journal-title":"JAMA Cardiol"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:46:57Z","timestamp":1741045617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498224000460"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104267","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary systemic amyloidosis: A brief overview","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104267"}}